AMPH

#2480
Amphastar Pharmaceuticals, Inc.
21.3800 USD
+0.09%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
21.3800
21.3800
Yıllık Aralık
17.0300
29.5200
Günlük Değişim
+0.09%
Aylık Değişim
+12.94%
6 aylık değişim
-12.31%
Yıllık Değişim
-12.31%
Önceki Kapanış
21.3600
Open
21.3800
Bid
Ask
Low
21.3800
High
21.3800
Hacim
57
Open full chart

Financials

Overview Rapor Statistics
Quarterly Annual
  • Market Capitalization 970.0143 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
13.19
Price to sales ratio
1.79

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

Haberler